한글목차

세계 유전자 편집 시장 규모는 2024년 46억 6,000만 달러에서 2029년까지 75억 9,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 10.2% 성장할 것으로 예상됩니다.

유전자교정 기술의 발전과 유전자교정 활용의 확대는 유전자교정 시장의 성장을 촉진하고 있습니다. 그러나 유전자 편집의 오프타겟 효과로 인한 여러 가지 문제에 직면해 있으며, 확장성 및 제조의 어려움과 함께 큰 장애물이 되고 있습니다.

"제품별로는 제품 부문이 2023년 유전자 편집 시장에서 가장 큰 점유율을 차지했습니다."

세포주 개발을 위한 실험 및 연구, 의약품 개발 및 신약 개발을 포함한 유전자 편집 프로세스에 대한 제품 수요는 유전자 시장에 필수적인 요소로 자리 잡고 있습니다. 유전자 편집 키트, 유전자 편집 시약, 유전자 편집 라이브러리와 같은 시약 및 소모품 및 소프트웨어 시스템으로서의 유전자 편집 제품은 제약 및 생명공학 기업, 학술 및 연구 기관에서 다양한 유전자 편집 워크플로우에 활용되고 있습니다. 서비스는 2023년 유전자 편집 시장에서 두 번째로 높은 점유율을 차지했습니다.

"기술별로는 CRISPR 기술이 2023년 유전자 편집 제품 시장에서 가장 높은 시장 점유율을 차지했습니다."

CRISPR 부문은 CRISPR 기술의 발전으로 인해 2023년 기술별 유전자 편집 제품 시장에서 가장 높은 점유율을 차지했으며, 이는 유전자 편집 분야에서 이 기술의 대규모 채택으로 이어지고 있습니다. 유전자 편집 제품은 Cas-9와 같은 시약, 벡터, 스크리닝 및 표적 식별을 위한 라이브러리, CRISPR 기반 유전자 편집 키트 등 광범위한 CRISPR 응용 분야에 사용되고 있습니다. 그럼에도 불구하고, TALEN 부문은 2023년 시장에서 두 번째 점유율을 차지할 것으로 예상됩니다.

"아시아태평양이 2024-2029년 유전자 편집 시장에서 가장 높은 CAGR로 성장하고 있습니다."

아시아태평양은 연구개발 활동에 대한 집중적인 투자, 정부 및 민간 기업의 유전자 편집 연구 자금 지원, 신약 개발 및 의약품 개발에 유전자 편집 기술 채택이 증가함에 따라 가장 빠르게 성장하는 시장으로 추정됩니다. 또한, 일본과 중국 등의 국가에서 희귀질환과 유전질환의 유병률 증가는 고령화 추세에 기인하고 있습니다. 이는 건강 관리 및 치료 분야에서 유전자 편집 기술의 채택을 촉진하고 시장 성장을 촉진하고 있습니다. 그러나 북미는 2023년 유전자 편집 시장에서 가장 큰 점유율을 차지했습니다.

이 보고서는 세계 유전자 편집 시장에 대해 조사 분석했으며, 주요 촉진 및 억제요인, 경쟁 상황, 향후 동향 등의 정보를 제공합니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

• 유전자 편집 시장 개요
• 북미의 유전자 편집 시장 : 유형별, 국가별(2023년)
• 유전자 편집 시장 : 지리적 성장 기회

제5장 시장 개요

• 소개
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
  • 주요 기업 평균판매가격 동향 : 소모품별(2023년)
  • 유전자 편집 키트·시약 평균 비용 범위(2021-2023년)
  • 서비스 평균판매가격 동향 : 유형별
  • 평균판매가격 : 지역별
• 공급망 분석
• 밸류체인 분석
• 생태계 분석
• 유전자 편집 시장에 대한 생성형 AI의 영향
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 특허 분석
• 주요 회의와 이벤트(2024-2025년)
• 규제 분석
  • 규제 상황
  • 규제기관, 정부기관, 기타 조직
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 사례 연구 분석
• 투자와 자금 조달 시나리오
• 무역 데이터 애널리틱스
  • 수입 데이터(2019-2023년)
  • 수출 데이터(2019-2023년)

제6장 유전자 편집 시장 : 제품별

• 소개
• 제품
• 서비스

제7장 유전자 편집 제품 시장 : 유형별

• 소개
• 시약·소모품
  • 유전자 편집 키트
  • 유전자 편집 라이브러리
  • 유전자 편집 시약
• 소프트웨어·시스템

제8장 유전자 편집 시약과 소모품 시장 : 기법별

• 소개
• 녹아웃
• 녹인
• 유전자 침묵
• 기타 기법

제9장 유전자 편집 제품 시장 : 기술별

• 소개
• CRISPR
• TALEN
• ZFN
• 염기 편집
• 안티센스
• RNAI
• 기타 기술

제10장 유전자 편집 제품 시장 : 용도별

• 소개
• 세포주 엔지니어링
• 유전체 편집
• Drug Discovery & Development
• 기타 용도

제11장 유전자 편집 제품 시장 : 최종사용자별

• 소개
• 제약·바이오테크놀러지 기업
• 학술·연구기관
• CRO·CDMO
• 기타 최종사용자

제12장 유전자 편집 서비스 시장 : 유형별

• 소개
• 세포주 개발·엔지니어링
• GRNA 합성·벡터 구축
• 라이브러리 구축·스크리닝
• 기타 서비스

제13장 유전자 편집 서비스 시장 : 용도별

• 소개
• 세포주 엔지니어링
• 유전체 편집
• Drug Discovery & Development
• 기타 용도

제14장 유전자 편집 서비스 시장 : 최종사용자별

• 소개
• 제약·바이오테크놀러지 기업
• 학술·연구기관
• 기타 최종사용자

제15장 유전자 편집 시장 : 지역별

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 기타 라틴아메리카
• 중동
  • 중동의 거시경제 전망
  • GCC 국가
  • 기타 중동
• 아프리카

제16장 경쟁 상황

• 소개
• 주요 기업 전략/유력 기업(2021-2024년)
• 매출 분석(2019-2023년)
• 시장 점유율 분석(2023년)
• 기업 평가와 재무 지표
  • 기업 평가
  • 재무 지표
• 브랜드/제품의 비교
  • THERMO FISHER SCIENTIFIC INC.(미국)
  • MERCK KGAA(독일)
  • GENSCRIPT(미국)
  • AGILENT TECHNOLOGIES, INC.(미국)
  • REVVITY, INC.(미국)
• 기업 평가 매트릭스 : 주요 기업(2023년)
• 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
• 경쟁 시나리오

제17장 기업 개요

• 주요 기업
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • GENSCRIPT
  • AGILENT TECHNOLOGIES, INC.
  • REVVITY, INC.
  • LONZA
  • TECAN TRADING AG
  • SANGAMO THERAPEUTICS
  • PRECISION BIOSCIENCES
  • CELLECTIS S.A.
  • REGENERON PHARMACEUTICALS, INC.
  • AMSBIO
  • CREATIVE BIOGENE
  • SYNTHEGO
  • TAKARA BIO INC.
  • BIO-TECHNE
  • CARIBOU BIOSCIENCES, INC.
  • BIONEER CORPORATION
  • REPROCELL INC.
• 기타 기업
  • ALSTEM INC.
  • NEW ENGLAND BIOLABS
  • INSCRIPTA, INC.
  • BIOCAT GMBH.
  • INTEGRATED DNA TECHNOLOGIES, INC.
  • COBO TECHNOLOGIES APS
  • GENECOPOEIA, INC.
  • HERA BIOLABS
  • STEMCELL TECHNOLOGIES.
  • AXOL BIOSCIENCE LTD.
  • CELLECTA, INC.
  • APPLIED STEMCELL

제18장 부록

영문목차

The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period.

Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.

"The product segment accounted for the largest share by offerings segment in the gene editing market in 2023"

By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutican & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.

"The CRISPR technology held the highest market share of the gene editing products market by technology in 2023"

By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.

"The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029."

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Thermo fisher scientific Inc. (US)
• Merck KGaA (Germany)
• GenScript (US)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Lonza (US)
• Tecan Trading AG (Switzerland)
• Sangamo therapeutics (US)
• Precision BioSciences (US)
• Cellectis S.A. (France)
• Regeneron Pharmaceuticals Inc. (US)
• AMSBIO (UK)
• Creative Biogene (US)
• Synthego (US)
• Takara Bio Inc. (Japan)
• Bio-Techne (US)
• Caribou Biosciences, Inc. (US)
• Bioneer corporation (South Korea)
• REPROCELL Inc. (Japan)

Research Coverage:

This research report categorizes the gene editing market by offerings (products and services), products by type (reagnets & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities (Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched product/services of the gene editing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the gene editing market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland), Sangamo therapeutics (US). Precision BioSciences (US), Cellectis S.A. (France), Regeneron Pharmaceuticals Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego (US), Takara Bio Inc. (Japan), Bio-Techne (US), Caribou Biosciences, Inc. (US) Bioneer corporation (South Korea), and REPROCELL Inc. (Japan).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
    • 2.2.1.1 Insights of primary experts
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GENE EDITING MARKET OVERVIEW
• 4.2 NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023)
• 4.3 GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing demand for personalized medicine
    • 5.2.1.2 Favorable government funding investments for gene editing projects
    • 5.2.1.3 Expanding applications of gene editing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Off-target effects and safety concerns
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising technological advancements in prime editing and bridge RNA
    • 5.2.3.2 Increasing burden of congenital disorders
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with scalability of gene editing workflows
    • 5.2.4.2 High equipment & manufacturing costs
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE (2023)
  • 5.4.2 AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021-2023
  • 5.4.3 AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE
  • 5.4.4 AVERAGE SELLING PRICE, BY REGION
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 IMPACT OF GENERATIVE AI ON GENE EDITING MARKET
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Next-generation sequencing
    • 5.9.1.2 Electroporation
    • 5.9.1.3 Microinjection
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Synthetic biology
    • 5.9.2.2 Data analysis
    • 5.9.2.3 High-throughput screening
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Single-cell analysis
    • 5.9.3.2 Optogenetics
    • 5.9.3.3 Gene delivery systems
• 5.10 PATENT ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 REGULATORY ANALYSIS
  • 5.12.1 REGULATORY LANDSCAPE
    • 5.12.1.1 North America
      • 5.12.1.1.1 US
      • 5.12.1.1.2 Canada
    • 5.12.1.2 Europe
      • 5.12.1.2.1 UK
    • 5.12.1.3 Asia Pacific
      • 5.12.1.3.1 China
      • 5.12.1.3.2 Japan
      • 5.12.1.3.3 South Korea
      • 5.12.1.3.4 Australia
      • 5.12.1.3.5 Rest of Asia Pacific
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID SSDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS
  • 5.15.2 GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA
  • 5.15.3 DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PUREDIT CRISPR CAS9 RNP SYSTEM
  • 5.15.4 EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING
  • 5.15.5 GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS
• 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.16.1 KEY INVESTMENTS & FUNDING ACTIVITIES, 2021-2024
• 5.17 TRADE DATA ANALYSIS
  • 5.17.1 IMPORT DATA, 2019-2023
  • 5.17.2 EXPORT DATA, 2019-2023

6 GENE EDITING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO DRIVE MARKET
• 6.3 SERVICES
  • 6.3.1 HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET

7 GENE EDITING PRODUCTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 REAGENTS & CONSUMABLES
  • 7.2.1 GENE EDITING KITS
    • 7.2.1.1 Increasing demand for mutation & screening kits in clinical settings to propel market
  • 7.2.2 GENE EDITING LIBRARIES
    • 7.2.2.1 Genetic screening for cancer research to fuel uptake
  • 7.2.3 GENE EDITING REAGENTS
    • 7.2.3.1 Ability to create animal models to support market growth
• 7.3 SOFTWARE & SYSTEMS
  • 7.3.1 INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET

8 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE

• 8.1 INTRODUCTION
• 8.2 KNOCK-OUT
  • 8.2.1 MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET
• 8.3 KNOCK-IN
  • 8.3.1 UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO DRIVE MARKET
• 8.4 GENE SILENCING
  • 8.4.1 ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO SUPPORT MARKET GROWTH
• 8.5 OTHER TECHNIQUES

9 GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 CRISPR
  • 9.2.1 ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE
• 9.3 TALENS
  • 9.3.1 INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
• 9.4 ZFN
  • 9.4.1 PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO BOOST DEMAND
• 9.5 BASE EDITING
  • 9.5.1 GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET
• 9.6 ANTISENSE
  • 9.6.1 INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH
• 9.7 RNAI
  • 9.7.1 WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE
• 9.8 OTHER TECHNOLOGIES

10 GENE EDITING PRODUCTS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 CELL LINE ENGINEERING
  • 10.2.1 ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION TO DRIVE MARKET
• 10.3 GENOME EDITING
  • 10.3.1 GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND
• 10.4 DRUG DISCOVERY & DEVELOPMENT
  • 10.4.1 UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO DRIVE MARKET
• 10.5 OTHER APPLICATIONS

11 GENE EDITING PRODUCTS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET
• 11.4 CROS & CDMOS
  • 11.4.1 PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO DRIVE MARKET
• 11.5 OTHER END USERS

12 GENE EDITING SERVICES MARKET, BY TYPE

• 12.1 INTRODUCTION
• 12.2 CELL LINE DEVELOPMENT & ENGINEERING
  • 12.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
• 12.3 GRNA SYNTHESIS & VECTOR CONSTRUCTION
  • 12.3.1 ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET
• 12.4 LIBRARY CONSTRUCTION & SCREENING
  • 12.4.1 INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET
• 12.5 OTHER SERVICES
  • 12.5.1 OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES.

13 GENE EDITING SERVICES MARKET, BY APPLICATION

• 13.1 INTRODUCTION
• 13.2 CELL LINE ENGINEERING
  • 13.2.1 HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET
• 13.3 GENOME EDITING
  • 13.3.1 GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND
• 13.4 DRUG DISCOVERY & DEVELOPMENT
  • 13.4.1 GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE
• 13.5 OTHER APPLICATIONS

14 GENE EDITING SERVICES MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 14.2.1 GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET
• 14.3 ACADEMIC & RESEARCH INSTITUTES
  • 14.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
• 14.4 OTHER END USERS

15 GENE EDITING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 15.2.2 US
    • 15.2.2.1 Growing investments by government authorities and private players to drive market
  • 15.2.3 CANADA
    • 15.2.3.1 Rise in research & development initiatives for genomics and biotechnology to augment growth
• 15.3 EUROPE
  • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 15.3.2 GERMANY
    • 15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market
  • 15.3.3 FRANCE
    • 15.3.3.1 Ongoing clinical trials and advanced genomic research to promote growth
  • 15.3.4 UK
    • 15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market
  • 15.3.5 ITALY
    • 15.3.5.1 Increasing availability of research funds to expedite growth
  • 15.3.6 SPAIN
    • 15.3.6.1 Booming biotechnology sector to contribute to market growth
  • 15.3.7 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 15.4.2 CHINA
    • 15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth
  • 15.4.3 JAPAN
    • 15.4.3.1 Growing focus on cancer research to fuel market
  • 15.4.4 INDIA
    • 15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth
  • 15.4.5 SOUTH KOREA
    • 15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth
  • 15.4.6 AUSTRALIA
    • 15.4.6.1 Favorable regulatory landscape to sustain growth
  • 15.4.7 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 15.5.2 BRAZIL
    • 15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 15.6.2 GCC COUNTRIES
    • 15.6.2.1 Kingdom of Saudi Arabia
      • 15.6.2.1.1 Increasing establishment of biotech startups to support market growth
    • 15.6.2.2 United Arab Emirates (UAE)
      • 15.6.2.2.1 Growing collaborations for genome sequencing to drive market
    • 15.6.2.3 Other GCC Countries
  • 15.6.3 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
• 16.3 REVENUE ANALYSIS, 2019-2023
• 16.4 MARKET SHARE ANALYSIS, 2023
  • 16.4.1 RANKING OF KEY MARKET PLAYERS
• 16.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 16.5.1 COMPANY VALUATION
  • 16.5.2 FINANCIAL METRICS
• 16.6 BRAND/PRODUCT COMPARISON
  • 16.6.1 THERMO FISHER SCIENTIFIC INC. (US)
  • 16.6.2 MERCK KGAA (GERMANY)
  • 16.6.3 GENSCRIPT (US)
  • 16.6.4 AGILENT TECHNOLOGIES, INC. (US)
  • 16.6.5 REVVITY, INC. (US)
• 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 16.7.1 STARS
  • 16.7.2 EMERGING LEADERS
  • 16.7.3 PERVASIVE PLAYERS
  • 16.7.4 PARTICIPANTS
  • 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 16.7.5.1 Company footprint
    • 16.7.5.2 Product footprint
    • 16.7.5.3 Service footprint
    • 16.7.5.4 Technology footprint
    • 16.7.5.5 Region footprint
• 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 16.8.1 PROGRESSIVE COMPANIES
  • 16.8.2 RESPONSIVE COMPANIES
  • 16.8.3 DYNAMIC COMPANIES
  • 16.8.4 STARTING BLOCKS
  • 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 16.8.5.1 Detailed list of key startups/SMEs
    • 16.8.5.2 Competitive benchmarking of key startups/SMEs
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 THERMO FISHER SCIENTIFIC INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products/Services offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product/Service launches & approvals
      • 17.1.1.3.2 Deals
      • 17.1.1.3.3 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 MERCK KGAA
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products/Services offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 GENSCRIPT
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products/Services offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product/Service launches & approvals
      • 17.1.3.3.2 Deals
      • 17.1.3.3.3 Expansions
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses and competitive threats
  • 17.1.4 AGILENT TECHNOLOGIES, INC.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products/Services offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Deals
      • 17.1.4.3.2 Expansions
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 REVVITY, INC.
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products/Services offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product/Service launches
      • 17.1.5.3.2 Deals
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weakness & competitive threats
  • 17.1.6 LONZA
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products/Services offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product/Service launches
  • 17.1.7 TECAN TRADING AG
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products/Services offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Deals
  • 17.1.8 SANGAMO THERAPEUTICS
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products/Services offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Deals
  • 17.1.9 PRECISION BIOSCIENCES
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products/Services offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Deals
  • 17.1.10 CELLECTIS S.A.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products/Services offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Deals
  • 17.1.11 REGENERON PHARMACEUTICALS, INC.
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products/Services offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Deals
  • 17.1.12 AMSBIO
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products/Services offered
  • 17.1.13 CREATIVE BIOGENE
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products/Services offered
  • 17.1.14 SYNTHEGO
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products/Services offered
    • 17.1.14.3 Recent developments
      • 17.1.14.3.1 Product/Service launches
      • 17.1.14.3.2 Deals
      • 17.1.14.3.3 Expansions
  • 17.1.15 TAKARA BIO INC.
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products/Services offered
    • 17.1.15.3 Recent developments
      • 17.1.15.3.1 Deals
      • 17.1.15.3.2 Expansions
  • 17.1.16 BIO-TECHNE
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products/Services offered
    • 17.1.16.3 Recent developments
      • 17.1.16.3.1 Deals
      • 17.1.16.3.2 Expansions
  • 17.1.17 CARIBOU BIOSCIENCES, INC.
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products/Services offered
    • 17.1.17.3 Recent developments
      • 17.1.17.3.1 Deals
  • 17.1.18 BIONEER CORPORATION
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products/Services offered
  • 17.1.19 REPROCELL INC.
    • 17.1.19.1 Business overview
    • 17.1.19.2 Products/Services offered
• 17.2 OTHER PLAYERS
  • 17.2.1 ALSTEM INC.
  • 17.2.2 NEW ENGLAND BIOLABS
  • 17.2.3 INSCRIPTA, INC.
  • 17.2.4 BIOCAT GMBH.
  • 17.2.5 INTEGRATED DNA TECHNOLOGIES, INC.
  • 17.2.6 COBO TECHNOLOGIES APS
  • 17.2.7 GENECOPOEIA, INC.
  • 17.2.8 HERA BIOLABS
  • 17.2.9 STEMCELL TECHNOLOGIES.
  • 17.2.10 AXOL BIOSCIENCE LTD.
  • 17.2.11 CELLECTA, INC.
  • 17.2.12 APPLIED STEMCELL

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS